L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 227.9 ILS -14.13% Market Closed
Market Cap: 114.6m ILS
Have any thoughts about
Lineage Cell Therapeutics Inc?
Write Note

P/OCF
Price to OCF

-1.4
Current
-0
Median
21.6
Industry
Lower than median
Lower than industry value

Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.

P/OCF
-1.4
=
Market Cap
114.6m ILS
/
Operating Cash Flow
-22m USD
All Countries
Close
 
US
L
Lineage Cell Therapeutics Inc
TASE:LCTX
Average P/OCF: 20.5
Negative Multiple: -1.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -239 316.7
US
Abbvie Inc
NYSE:ABBV
18.9
US
Amgen Inc
NASDAQ:AMGN
21.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -137.9
US
Gilead Sciences Inc
NASDAQ:GILD
11.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -470.1
AU
CSL Ltd
ASX:CSL
31.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -75.9
NL
argenx SE
XBRU:ARGX
Negative Multiple: -138.6

P/OCF Forward Multiples

Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A

See Also

Discover More